Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It places an enormous burden on the
patients, caregivers and the society at large. As a chronic illness, AF accrues significant costs related to clinical presentation,
complications and loss of productivity. Novel invasive approaches to AF promise a cure in some patients and a significant
reduction in AF burden in others, but are very expensive. This paper will address the cost of conventional and invasive
strategies in AF care and will review the evidence on the comparative cost effectiveness of these approaches.
Keywords: Atrial fibrillation, catheter ablation, cost-effectiveness, aniarrhythmic therapy, antithrombotic therapy
Rights & PermissionsPrintExport